Psychiatry Investig Search


Psychiatry Investig > Volume 18(4); 2021 > Article
Byeon, Kim, Byun, Lee, Jeon, Ko, Sung, Han, Joung, Lee, Jung, Lee, Yi, Lee, and KBASE Research Group: Validation of the Korean Version of the Anosognosia Questionnaire for Dementia



Anosognosia is a common phenomenon in individuals with dementia. Anosognosia Questionnaire for dementia (AQ-D) is a well-known scale for evaluating anosognosia. This study aimed to establish a Korean version of the AQ-D (AQ-D-K) and to evaluate the reliability and validity of the AQ-D-K in patients with Alzheimer’s disease (AD) dementia.


We translated the original English version of AQ-D into Korean (AQ-D-K). Eighty-four subjects with very mild or mild AD dementia and their caregivers participated. Reliability of AQ-D-K was assessed by internal consistency and one-month test-retest reliability. Construct validity and concurrent validity were also evaluated.


Internal consistencies of the AQ-D-K patient form and caregiver form were high (Cronbach alpha 0.95 and 0.93, respectively). The test-retest reliability of AQ-D-K measured by intra-class correlation coefficient was 0.84. Three factors were identified: 1) anosognosia of instrumental activity of daily living; 2) anosognosia basic activity of daily living; and 3) anosognosia of depression and disinhibition. AQ-D-K score was significantly correlated with the clinician-rated anosognosia rating scale (ARS), center for epidemiological studies-depression scale (CES-D) and state-trait anxiety inventory (STAI).


The findings suggest that the AQ-D-K is a reliable and valid scale for evaluating anosognosia for AD dementia patients using Korean language.


Anosognosia is a common phenomenon associated with Alzheimer’s disease (AD) dementia and occurs in about 42% to 80% of AD dementia patients [1,2]. It is observed not only in advanced AD dementia cases but also in relatively early cases of the disease [2]. Given that anosognosia can lead to refusal for appropriate treatment or care resulting in poorer treatment outcome and increased caregiver distress, an accurate assessment of anosognosia in dementia is important for clinical practice and care planning [3].
The anosognosia questionnaire for dementia (AQ-D) is a well-known, widely used scale for assessing anosognosia in AD dementia patients [4]. It measures the degree of anosognosia based on the discrepancy of the symptom severity reported by patient and caregiver [4] and was reported to be highly reliable and valid [5,6]. The original English version of AQ-D was previously translated into the Japanese and Italian [7,8]. Nevertheless, AQ-D was unavailable in Korean. Therefore, the aim of the current study is to establish the Korean version of the AQ-D and to verify reliability and validity in Korean older adults with AD dementia.


Translation of the AQ-D into Korean

For the translation of the original English version of the AQ-D into Korean, we first obtained permission from the authors of the original English version. Then, a bilingual clinical neuropsychologist translated the English version into Korean. Back-translation of the Korean version into English was performed by a bilingual psychiatrist. After back-translation, four psychiatrists (DYL, KK, SYJ, and WJK) and a clinical neuropsychologist (DY) discussed the similarity and suitability of the translated Korean version. Refinement steps then followed to ensure appropriateness of the phrases and words used in the questionnaire to be mindful of cultural differences. Similar to the original English version, the final Korean version of the AQ-D (AQ-D-K) has 30 items (Supplementary Table 1 in the online-only Data Supplement)


A total of 84 AD dementia patients and their caregivers, who participated in the Korean Brain Aging study for the Early diagnosis and prediction of Alzheimer’s disease (KBASE), an ongoing prospective cohort study [9], were included in this study. All AD dementia patients (age range 55-87 years) met the criteria for the diagnosis of dementia in the Diagnostic and Statistical Manual of Mental Disorders 4th Edition (DSM-IV) [10] and the National Institute on Aging-Alzheimer’s Association (NIA-AA) criteria for the diagnosis of probable AD [11], and had clinical dementia rating (CDR) [12] global score of 0.5 or 1. All caregivers were family members who were able to provide reliable information about the patients; they either lived together or kept regular contacts at least three times a week with the patients. The exclusion criteria for both patients and caregivers were as follow: 1) presence of current major depressive disorder or other major psychiatric disorders; or 2) inability to understand and speak the Korean language used in the AQ-D-K.

Clinical assessments

All AD dementia patients were administered standardized clinical assessments based on the KBASE clinical assessment protocol which incorporated the the Korean version of Consortium to Establish a Registry for Alzheimer’s Disease (CERAD-K) clinical assessment [13,14] by board-certified psychiatrists. The KBASE protocol included the following assessments: CDR, Blessed Dementia Scale-Activity of Daily Living (BDS-ADL) [14,15] as a measure for ADL, and Neuropsychiatric Inventry (NPI) [16,17] as a measure for behavior and psychological symptoms based on caregiver’s report. The Center for Epidemiologic Studies Depression scale (CES-D) [18,19] and the State-Trait Anxiety Inventory (STAI) [20,21] were also administered to all patients in order to evaluate depression and anxiety symptoms, respectively. The Seoul Informant Report Questionnaire for Dementia (SIRQD) [22], a dementia screening questionnare based on informant report, were was administered to caregivers to investigate objective cognitive decline. All patients were also evaluated by a psychiatrist using the Anosognosia Rating Scale (ARS), which is an anosognosia evaluation instrument based on a clinical judgement [23]. ARS was rated in a four-point rubric score as full awareness, shallow awareness, no awareness, or denial of impairment. This study was approved by the Institutional Review Board of Seoul National University Hospital (IRB 1706-065-859), and all patients and their caregivers gave informed consent for the study participation.

Neuropsychological assessments

All patiens underwent comprehensive neuropsychological assessment, administered according to a standardized protocol incorporating the CERAD-K neuropsychological battery [24] by trained psychometrists supervised by a neuropsychologist. The protocol included 8 tests in the CERAD-K neuropsychological battery, which are the Mini-Mental State Examination (MMSE) , Verbal Fluency (VF), 15-item Boston Naming Test (BNT), Word List Memory (WLM), Word List Recall (WLR), Word List Recognition (WLRc), Constructional Praxis (CP), Constructional Recall (CR) [24], and the Stroop color word test (SCWT) [25]. CERAD total score I (TS I) [26], which is calculated by summing the scores of six tests included in the CERAD-K neuropsychological battery (i.e., VF, BNT, WLM, WLR, WLRc, and CP), and CERAD total score II, which is the summation of TS I and score of contstruction recall [27] were also used as the measures of global cognition.

Administation and scoring of the AQ-D-K

The AQ-D-K consists of two forms: the patient form and the caregiver form. Each of the two form was administered to patient or his/her caregiver, respectively. The two forms have the same sentence structure and content except for the subject of the statements. Similar to the original instruction, patients were interviewed first and then their caregivers. Patients and their caregivers were requested to answer ‘never’, ‘sometimes’, ‘usually’, or ‘always’ for each item (scores ranging from 0 to 3). The AQ-D-K patient score (PS) and caregiver score (CS) were obtained by adding up the scores of each item of the patient form and caregiver form, respectively. Consistent with the original version, the final score, AQ-D-K total score (TS), was the difference between CS and PS. Thus, positive TS indicates that the caregiver rates the patient as more impaired than the patient’s own self-evaluation [4].
The 30 items of the AQ-D-K, similar the original AQ-D, are categorized into two subscales. The first subscale (i.e., cognitive subscale; TS-cog) includes 22 items for cognitive function and ADL (item No. 1-22), whereas the second subscale (i.e., behavioral subscale; TS-beh) consists of 8 items for neuropsychiatric aspects (item No. 23-30). The total score is the difference of score sum for each of the two subscales between caregiver and patient form, respectively.
In order to assess the test-retest reliability, the AQ-D-K was administered again to 10 randomly selected AD dementia patients and their caregivers four weeks after the initial administration.

Statistical analyses


In order to verify the reliability of the AQ-D-K, internal consistency and test-retest reliability were examined. The internal consistency for each of the patient and caregiver form was assessed by Cronbach α coefficient [28]. Four-week test-retest reliability for the patient and caregiver form was assessed using the intraclass correlation coefficient (ICC) [28].

Construct validity

To evaluate construct validity, exploratory factor analysis on 30 items of the AQ-D-K was performed by using principal component analysis. Inspection of eigen values and a scree plot produced by the principal component analysis with varimax rotation indicated that 3 to 5 factors were appropriate for consideration. After examining 3 to 5 factor solutions, we chose the final model considering the interpretability of factor structure and the accordance with the results from previous validation studies [6-8]. We removed items with communality of 0.2 or less [29]. Retained factors should have items with a loading greater than 0.4 [30].

Concurrent validity

To verify the concurrent validity of the AQ-D-K, the associations of TS, TS-cog, TS-beh with ARS score were first examined by using Spearman’s correlation analysis. Additionally, Pearson correlation analyses were conducted to assess the relationships of TS, TS-cog and TS-beh with SIRQD, CDR sum of boxes (SOB), BDS-ADL, NPI, STAI, and CES-D scores. Pearson correlation analyses were also performed to examine the relationships of TS, TS-cog, TS-beh with the z-score of each neuropsychological test or CERAD total score.
In all analysis, p<0.05 was taken to indicate statistical significance. All statistical analyses were performed using IBM SPSS Statistics 23 (IBM Corporation, Armonk, NY, USA).


Demographic characteristics

The demographic and clinical characteristics of the study participants are summarized in Table 1. Caregivers consisted of spouses (41.7%), daughters (36.9%), sons (15.5%) and daughter in law (6.0%).
As for the patients, 69% were women, and the average years of educational attainment was 9. CDR was 0.5 (questionable dementia) in 34.5% and 1 (mild dementia) in the rest of the patients. The average score of MMSE was 16.58, and the average z scores of CERAD TS I and TS II were -2.25 and -2.34, respectively. The averages of TS, TS-Cog, and TS-Beh, which are the main variables of interest in this study, are 8.86, 6.80 and 1.76, respectively. Another measure of anosognosia, ARS, had average score of 1.55. Other mean and standard deviation of the variables including BDS-ADL, NPI, CES-D, STAI and individual neuropsychological test scores are described in Table 1.


Internal consistency measured by the Cronbach’s coefficient α was 0.95 for patient form and 0.93 for caregiver form. ICC between test and retest score was 0.79 for patient form and 0.82 for caregiver form.

Construct validity

Through the exploartory factor analysis, 3 separate facotrs, i.e., ‘Instrumental acitivity of daily living (iADL)’, ‘Basic activity of daily living (bADL)’ and ‘Depression disinhibition’ were finally extracted (Table 2). We did not include the four items that were double-loaded for two factors (A-4, A-5, A-6, and A-13) (Table 2) and the item with communality less than 0.20 (B-28; communality value: 0.150) in final model. For the final model with three factors, the Kaiser-Meyer-Olkin (KMO) value was 0.85 and the significance level of the Bartlett’s sphericity test was less than 0.001, indicative of a suitable model. The variance explained by the three factors (R2) was 50.45%.

Concurrent validity

As shown in Table 3, TS, TS-cog, and TS-beh had significant positive correlations with ARS scores, whereas they did not show any significant correlation with SIRQD, CDR-SOB, BDS-ADL, and NPI scores. TS, TS-cog, and TS-beh also did not show any significant correlations with any neuropsychological test scores (Table 4).
Additionally, TS and TS-cog showed significant negative correlation with CES-D and STAI scores (Table 3). TS-beh also had significant correlation with CES-D score and trend toward significance (p=0.06) with STAI score.


In this study, we developed the AQ-D-K by translating the English version of the AQ-D and verified the reliability and validity of the AQ-D-K. In regard of the reliability of the AQ-D-K, Cronbach α value, a measure of internal consistency [31], is more than 0.9 for both patient form and caregiver form. This result indicates that the items of AQ-D-K consistently evaluate a concept of anosognosia. Additionally, ICC between test and retest was approximately 0.8 for both forms, which supports that AQ-D-K has good test-retest reliability.
A factor analysis revealed that the AQ-D-K is composed of three primary factors: iADL, bADL, and depression & disinhibition factor. This finding is generally consistent with the original design of the AQ-D, which included both cognitive or functional and neuropsychiatric subscales, and with the factors structures of the original English version or other language versions of AQ-D (Table 5). However, the number of factors of the AQ-D-K (i.e., three factors) was not exactly the same with those of the original English version or the Italian version of the AQ-D, which had four factors [6,7]. This discrepancy may be related to the difference of dementia severity of patients included in the studies. While the studies for the English and Italian version included AD dementia patients with wide range of severity from very mild to severe [6] or from very mild to moderate [7], our study included only very mild or mild AD dementia patients. The clinical manifestations of impairment and awareness on the impairments can vary according to the severity of dementia [32]. Depression has the highest prevalence in mild dementia compared to severe dementia, while apathy and disinhibition are not frequent in mild dementia but become pronounced as the severity of dementia progresses [33-35]. Moreover, certain symptoms related to apathy [e.g., loss of interest (B-29)] and disinhibition [e.g., irritability (B-25) and crying (B-26)] are commonly associated with depression. Therefore, it is more likely that such symptoms are manifestations of depression rather than apathy or disinhibition in mid dementia, whereas they are more closely related to apathy or disinhibition in severe dementia.
However, although the validation study for the Japanese AQ-D [8] included very mild or mild patients, it demonstrated that the Japanese AQ-D had four factors (Table 5). Therefore, language difference of the instruments and cultural background of participants may also be considered. When a test is constructed in one culture only and then transferred to another culture and language, handicap in standardization process appear to be unavoidable [36]. Regarding the ‘Problems with signing the name’ item in AQ-D-K, signature is a basic life skill that is essential in everyday life in Western countries. But in Korea, especially the elderly uses a wooden stamp more often and rarely uses signature. In this respect, unlike the original scale, ‘Problems with signing the name’ was not loaded alone in the ‘bADL’ factor but double loaded in ‘depression and disinhibition’. So, this item was excluded from the final factor analysis.
Consistent with the previous report on the Japanese version of AQ-D [8], a positive correlation was found between TS of the AQ-D-K and ARS score [23], which supports concurrent validity of the AQ-D-K. Moreover, TS-cog and TS-beh, as well as TS, significantly correlated with ARS score, indicating that the two subscales of the AQ-D-K is useful for evaluating anosognosia on cognitive and neuropsychiatric domains of AD dementia symptoms. In contrast, neither TS nor TS-cog and TS-beh showed significant correlation with any objective measures for cognitive and functional impairments including SIQRD, CDR-SOB, BDS-ADL or neuropsychological tests scores in this study. This suggests that the degree of anosognosia, measured by the AQ-D-K, may be independent of cognitive symptoms and functional impairments. This is consistent with the result of previous reports on lack of significant associations between the neuropsychological test scores and anosognosia measured by AQ-D in mild AD [2]. Probably, this study only included patients with very mild or mild AD, so it is presumed that anosognosia was not related to clinical severity. Interestingly, there was trend for significance in negative correlation of AQ-D-K scores with both STAI and CES-D scores. The finding implies that depressive or anxious patients may evaluate their own symptoms more negatively. This is in line with the previous reports that AD patients with depression and anxiety symptoms show more apparent awareness about the disease [37-39].
A couple of limitations should be mentioned. First, the current study included only AD dementia patients with very mild or mild severity. Although we verified that AQ-D-K is a reliable and valid instrument for the evaluation of anosognosia in those patients, further studies including more advanced AD dementia and other types of dementia patients are still required to increase the generalizability of the AQ-D-K. In addition, relatively small sample size also needs to be mentioned. In general, appropriate sample size for factor analysis is known to be more than three times of the number of variables (items) being analyzed. Given the number of AQ-D-K items is 30, 84 subjects included in our study is slightly less than the recommended 90 subjects. If the sample size is not enough, standard error of factor loading increases, which may influence the factor structure [40].
In conclusion, the findings from the present study suggest that AQ-D-K can be useful in evaluating anosognosia in AD dementia patients using Korean language. The AQ-D-K is expected to facilitate the assessment of anosognosia for dementia patients in clinical practice and research.

Supplementary Materials

The online-only Data Supplement is available with this article at


We would like to thank Dr. Sergio Starkstein who permitted to translate the original English version of AQ-D into Korean version. We also thank the participants and their caregivers who attend to this study. Part of the statistical analysis process was performed with the support of the Medical Research Collaborating Center (MRCC) of the Seoul National University Hospital. This study was supported by a grant from the Ministry of Science, ICT, and Future Planning, Republic of Korea (Grant No: NRF2014M3C7A1046042) and a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (Grant No: HI18C0630 & HI19C0149).


The authors have no potential conflicts of interest to disclose.


Authors’ contribution

Conceptualization: Dong Young Lee, Dahyun Yi. Data curation: Kiyoung Sung, Dongkyun Han, Haejung Joung, Younghwa Lee, Gijung Jung, Han Na Lee. Formal analysis: Gi Hwan Byeon, Dahyun Yi, Dong Young Lee. Funding acquisition: Dong Young Lee. Investigation: Woo Jin Kim, Min Soo Byun, Jun Ho Lee, So Yeon Jeon, Kang Ko. Methodology: Gi Hwan Byeon, Woo Jin Kim, Dahyun Yi, Dong Young Lee. Project administration: Gi Hwan Byeon, Dahyun Yi, Dong Young Lee. Resource: Woo Jin Kim, Min Soo Byun, Jun Ho Lee, So Yeon Jeon, Kang Ko. Software: Gi Hwan Byeon, Dahyun Yi, Dong Young Lee. Supervision: Dahyun Yi, Dong Young Lee. Validation: Gi Hwan Byeon. Writing—original draft: Gi Hwan Byeon, Dahyun Yi, Dong Young Lee. Writing—review & editing: all authors.

Table 1.
Demographic and clinical characteristics
Patient (N=84) Caregiver (N=84)
Mean (SD) Mean (SD)
Sex [female, N (%)] 58 (69.0) 52 (61.9)
Age (years) 73.08 (8.13) 56.51 (13.78)
Education (years) 8.97 (5.31) 13.78 (3.44)
CDR [N (%)]
 0.5 29 (34.5)
 1 55 (65.5)
TS 8.86 (17.99)
TS-Cog 7.10 (15.05)
TS-Beh 1.76 (4.261)
BDS-ADL 3.80 (1.06)
NPI 7.20 (9.29)
CES-D 32.32 (9.91)
STAI 81.12 (22.22)
ARS 1.55 (0.75)
VF (z score) -1.21 (0.96)
BNT (z score) -0.62 (1.28)
MMSE (raw score) 16.58 (4.13)
MMSE (z score) -3.08 (1.43)
WLM (z score) -1.57 (1.18)
CP (z score) -0.92 (1.86)
WLR (z score) -2.27 (0.78)
WLRc (z score) -2.66 (1.56)
CR (z score) -1.79 (0.54)
SCWT (z score) -1.28 (1.12)
TS I (z score) -2.25 (1.14)
TS II (z score) -2.34 (1.08)

SD: standard deviation, CDR: Clinical Dementia Rating, TS: Total score of Anosognosia Questionnaire for Dementia Korean version, TS-Cog: Total score of cognitive subscale, TS-Beh: Total score of behavioral subscale, BDS-ADL: Blessed Dementia Scale-Activity of Daily Living, NPI: Neuropsychiatric Inventry, CES-D: The Center for Epidemiologic Studies Depression scale, STAI: State-Trait Anxiety Inventory, ARS: Anosognosia Rating Scale, VF: Verbal Fluency, BNT: Boston Naming Test, MMSE: Mini-Mental State Examination, WLM: word list memory, CP: constructional praxis, WLR: word list recall, WLRc: word list recognition, CR: constructional recall, SCWT: Stroop color word test, TS I: CERAD total score I, TS II: CERAD total score II

Table 2.
Factor loading of reduced items (with varimax rotation)
Items iADL bADL Depression and disinhibition
A-12. Problems with remembering appointments 0.850
A-22. Problems with doing clerical work 0.817
A-16. Problems with remembering shopping lists 0.814
A-10. Problems with handling money 0.788
A-8. Problems with remembering where things were left 0.777
A-3. Problems with remembering telephone calls 0.759
A-7. Problems with keeping belongings in order 0.734
A-1. Problems with remembering dates 0.666
A-9. Problems with writing 0.616
B-23. More rigid and inflexible about decisions 0.607
A-18. Problems with understanding the plot of a movie 0.597
A-2. Problems with orienting in new places 0.560
A-15. Problems with doing mental calculations 0.560
A-20. Problems with doing home activities 0.537
A-4. Problems with understanding conversations 0.464 0.453
A-11. Problems with orientation in your neighborhood 0.739
A-14. Problems with communicating with people 0.619
A-21. Problems with feeding oneself 0.557
A-5. Problems with signing the name 0.554 0.522
A-6. Problems with understanding the newspaper 0.522 0.554
A-19. Problems with orienting in the house 0.549
A-17. Problems with bladder control 0.523
B-30. More depressed 0.733
B-25. More irritable 0.641
B-26. More frequent crying episodes 0.638
B-24. More egotistical and self-centered 0.614
A-13. Problems with practicing favorite hobbies 0.499 0.508
B-29. Less interest in favorite activities 0.491
B-27. Laughing inappropriately 0.445

The number written represent loading ≥0.40. Only items with bold numbers are included to separate factors. A: cognitive deficit, B: behavioral problem (Mirogoleli et al, 1996). iADL: instrumental activity of daily living, bADL: basic activity of daily living

Table 3.
Comparison of factor structure between AQ-D-K and previous validated AQ-D (see with Supplementary Table 2 in the online-only Data Supplement)
Author Year Factor structure Items
Starkstein et al. [6] 2006 1. iADL 1, 2, 3, 4, 7, 8, 10, 12, 15, 16, 18, 22
2. bADL 5, 17, 19, 21
3. Depression 23, 24, 25, 26, 13, 30
4. Disinhibition 27, 28
Sato et al. [8] 2007 1. ADL 10, 13, 14, 15, 17, 18, 19, 20, 21, 22
2. Episodic memory and orientation 1, 2, 3, 4, 5, 6, 8
3. Disinhibited behavior 25, 26, 27, 28
4. Apathy and depression 23, 24, 29, 30
Gambina et al. [7] 2015 1. iADL 1, 2, 3, 6, 7, 8, 10, 11, 12, 13, 15, 16, 18, 20, 22, 29
2. bADL 5, 9, 14, 17, 19, 21
3. Depression and apathy 4, 23, 24, 26, 30
4. Disinhibition 26, 27, 28
Byeon et al. (AQ-D-K) 2020 1. iADL 1, 2, 3, 7, 8, 9, 10, 12, 15, 16, 18, 20, 22, 23
2. bADL 11, 14, 17, 19, 21
3. Depression and disinhibition 24, 25, 26, 27, 29, 30

iADL: instrumental activity of daily living, bADL: basic activity of daily living, AQ-D-K: Anosognosia Questionnaire for Dementia Korean version

Table 4.
Correlation with other anosognosia scale (ARS), scales of depression, anxiety and neuropsychiatric symptoms
TS TS-Cog TS-Beh
ARS 0.301** 0.288** 0.245*
SIRQD 0.136 0.111 0.184
CDR-SOB 0.197 0.208 0.095
BDS-ADL 0.098 0.095 0.079
NPI -0.054 -0.047 -0.059
STAI -0.267* -0.260* -0.210
CES-D -0.317** -0.301** -0.275*

* p<0.05,

** p<0.01,

*** p<0.001.

AQ-D-K: Anosognosia Questionnaire for Dementia Korean version, ARS: anosognosia rating scale, CDR: clinical dementia rating, BDS-ADL: blessed dementia scaleactivities of daily living, NPI: neuropsychiatry inventory, SIRQD: Seoul informant report questionnaire for dementia, CES-D: center for epidemiological studies-depression scale, STAI: state-trait anxiety inventory, TS: AQ-D-K total score, TS-Cog: Cognitive part of AQD-K total score, TS-Beh: Behavioral part of AQ-D-K total score

Table 5.
Correlation between AQ-D-K and Neuropsychological tests
Neuropsychological tests (z-scores) TS TS-Cog TS-Beh
VF 0.003 0.003 0.034
BNT -0.057 -0.073 0.018
MMSE-KC 0.071 -0.085 <0.001
WLM 0.077 0.064 0.099
CP 0.089 0.093 0.049
WLR -0.142 -0.145 -0.087
WLRc 0.069 0.079 0.011
CR 0.002 0.010 -0.027
SCWT 0.114 0.111 0.091
TS I -0.005 -0.007 0.004
TS II 0.007 <0.001 0.029

* p<0.05,

** p<0.01,

*** p<0.001.

TS: Total score of Anosognosia Questionnaire for Dementia Korean version, TS-Cog: Cognitive part of AQ-D-K total score, TS-Beh: Behavioral part of AQ-D-K total score, AQ-D-K: Anosognosia Questionnaire for Dementia Korean version, CERAD-K: the Korean version of Consortium to Establish a Registry for Alzheimer’s Disease. VF: verbal fluency, BNT: Modified Korean version of Boston Naming Test, MMSE-KC: Mini-Mental State Examination in the Korean version of the CERAD assessment packet, WLM: word list memory, WLR: word list recall, WLRc: word list recognition, CP: constructional praxis, CR: constructional recall, SCWT: Stroop color word test. TS I: CERAD-K total score I, TS II: CERAD-K total score II


1. Agnew SK, Morris RG. The heterogeneity of anosognosia for memory impairment in Alzheimer’s disease: a review of the literature and a proposed model. Aging Ment Health 1998;2:7-19.
2. Orfei MD, Blundo C, Celia E, Casini AR, Caltagirone C, Spalletta G, et al. Anosognosia in mild cognitive impairment and mild Alzheimer’s disease: frequency and neuropsychological correlates. Am J Geriatr Psychiatry 2010;18:1133-1140.
crossref pmid
3. DeBettignies BH, Mahurin RK, Pirozzolo FJ. Insight for impairment in independent living skills in Alzheimer’s disease and multi-infarct dementia. J Clin Exp Neuropsychol 1990;12:355-363.
crossref pmid
4. Migliorelli R, Teson A, Sabe L, Petracca G, Petracchi M, Leiguarda R, et al. Anosognosia in Alzheimer’s disease: a study of associated factors. J Neuropsychiatry Clin Neurosci 1995;7:338-344.
5. Starkstein SE, Sabe L, Chemerinski E, Jason L, Leiguarda R. Two domains of anosognosia in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 1996;61:485-490.
crossref pmid pmc
6. Starkstein SE, Jorge R, Mizrahi R, Robinson RG. A diagnostic formulation for anosognosia in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2006;77:719-725.
crossref pmid pmc
7. Gambina G, Valbusa V, Corsi N, Ferrari F, Sala F, Broggio E, et al. The Italian validation of the Anosognosia Questionnaire for Dementia in Alzheimer’s disease. Am J Alzheimers Dis Other Demen 2015;30:635-644.
crossref pmid
8. Sato J, Nakaaki S, Murata Y, Shinagawa Y, Matsui T, Hongo J, et al. Two dimensions of anosognosia in patients with Alzheimer’s disease: reliability and validity of the Japanese version of the Anosognosia Questionnaire for Dementia (AQ-D). Psychiatry Clin Neurosci 2007;61:672-627.
crossref pmid
9. Byun MS, Yi D, Lee JH, Choe YM, Sohn BK, Lee JY, et al. Korean brain aging study for the early diagnosis and prediction of Alzheimer’s disease: methodology and baseline sample characteristics. Psychiatry Investig 2017;14:851-863.
crossref pmid pmc
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorderss: DSM-IV-TR. Washington, DC: APA Press; 2000.

11. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7:263-269.
crossref pmid pmc
12. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.

13. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology 1989;39:1159-1165.
14. Lee JH, Lee KU, Lee DY, Kim KW, Jhoo JH, Kim JH, et al. Development of the Korean version of the Consortium to Establish a Registry for Alzheimer’s Disease Assessment Packet (CERAD-K): clinical and neuropsychological assessment batteries. J Gerontol B Psychol Sci Soc Sci 2002;57:P47-P53.
crossref pmid
15. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968;114:797-811.
crossref pmid
16. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
crossref pmid
17. Choi SH, Na DL, Kwon HM, Yoon SJ, Jeong JH, Ha CK. The Korean version of the neuropsychiatric inventory: a scoring tool for neuropsychiatric disturbance in dementia patients. J Korean Med Sci 2000;15:609-615.
crossref pmid pmc
18. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385-401.

19. Cho MJ, Kim KH. Diagnostic validity of the CES-D (Korean version) in the assessment of DSM-III-R major depression. J Korean Neuropsychiatr Assoc 1993;32:381-399.

20. Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA. Manual for the State-Trait Anxiety Inventory (STAI). Palo Alto, CA: Consulting Psychologists Press; 1983.

21. Han DW, Lee CH, Tak JK. Standardization of Spielberger Stait-Trait Anxiety Inventory Spielberger. Resource from Korean Psychologica Association Conference 1993;505-512.

22. Lee DY, Kim KW, Yoon JC, Jhoo JH, Lee JH, Woo JI. Development of an Informant Report Questionnaire for Dementia Screening: Seoul Informant Report Questionnaire for Dementia (SIRQD). J Korean Neuropsychiatr Assoc 2004;43:209-218.

23. Reed BR, Jagust WJ, Coulter L. Anosognosia in Alzheimer’s disease: relationships to depression, cognitive function, and cerebral perfusion. J Clin Exp Neuropsychol 1993;15:231-244.
crossref pmid
24. Lee DY, Lee KU, Lee JH, Kim KW, Jhoo JH, Kim SY, et al. A normative study of the CERAD neuropsychological assessment battery in the Korean elderly. J Int Neuropsychol Soc 2004;10:72-81.
crossref pmid
25. Seo EH, Lee DY, Choo IH, Kim SG, Kim KW, Youn JC, et al. Normative study of the Stroop Color and Word Test in an educationally diverse elderly population. Int J Geriatr Psychiatry 2008;23:1020-1027.
crossref pmid
26. Chandler M, Lacritz L, Hynan L, Barnard H, Allen G, Deschner M, et al. A total score for the CERAD neuropsychological battery. Neurology 2005;65:102-106.
crossref pmid
27. Seo EH, Lee DY, Lee JH, Choo IH, Kim JW, Kim SG, et al. Total scores of the CERAD neuropsychological assessment battery: validation for mild cognitive impairment and dementia patients with diverse etiologies. Am J Geriatr Psychiatry 2010;18:801-809.
crossref pmid
28. Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 2007;60:34-42.
crossref pmid
29. Child D. The Essentials of Factor Analysis. New York: A&C Black; 2006.

30. Hair JF, Black WC, Babin BJ, Anderson RE, Tatham RL. Multivariate Data Analysis. NJ: Prentice Hall Upper Saddle River; 1998.

31. Cronbach LJ, Meehl PE. Construct validity in psychological tests. Psychol Bull 1955;52:281-302.
crossref pmid
32. Kashiwa Y, Kitabayashi Y, Narumoto J, Nakamura K, Ueda H, Fukui K. Anosognosia in Alzheimer’s disease: association with patient characteristics, psychiatric symptoms and cognitive deficits. Psychiatry Clin Neurosci 2005;59:697-704.
crossref pmid
33. Lopez OL, Becker JT, Sweet RA, Klunk W, Kaufer DI, Saxton J, et al. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 2003;15:346-353.
crossref pmid
34. Landes AM, Sperry SD, Strauss ME. Prevalence of apathy, dysphoria, and depression in relation to dementia severity in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 2005;17:342-349.
crossref pmid
35. Tagariello P, Girardi P, Amore M. Depression and apathy in dementia: same syndrome or different constructs? A critical review. Arch Gerontol Geriatr 2009;49:246-249.
crossref pmid
36. Miron M. A validation study of a transferred group intelligence test (1). Int J Psychol 1977;12:193-205.

37. Derouesne C, Thibault S, Lagha-Pierucci S, Baudouin-Madec V, Ancri D, Lacomblez L. Decreased awareness of cognitive deficits in patients with mild dementia of the Alzheimer type. Int J Geriatr Psychiatry 1999;14:1019-1030.
38. Harwood DG, Sultzer DL, Wheatley MV. Impaired insight in Alzheimer disease: association with cognitive deficits, psychiatric symptoms, and behavioral disturbances. Neuropsychiatry Neuropsychol Behav Neurol 2000;13:83-88.
39. Clare L, Nelis SM, Martyr A, Roberts J, Whitaker CJ, Markova IS, et al. The influence of psychological, social and contextual factors on the expression and measurement of awareness in early-stage dementia: testing a biopsychosocial model. Int J Geriatr Psychiatry 2012;27:167-177.
crossref pmid
40. MacCallum RC, Widaman KF, Zhang S, Hong S. Sample size in factor analysis. Psychol Methods 1999;4:84-99.


Browse all articles >

Editorial Office
#522, 27, Seochojungang-ro 24-gil, Seocho-gu, Seoul 06601, Korea
Tel: +82-2-537-6171    Fax: +82-2-537-6174    E-mail:                

Copyright © 2021 by Korean Neuropsychiatric Association.

Developed in M2PI

Close layer
prev next